CY1121464T1 - Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας - Google Patents

Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας

Info

Publication number
CY1121464T1
CY1121464T1 CY20191100299T CY191100299T CY1121464T1 CY 1121464 T1 CY1121464 T1 CY 1121464T1 CY 20191100299 T CY20191100299 T CY 20191100299T CY 191100299 T CY191100299 T CY 191100299T CY 1121464 T1 CY1121464 T1 CY 1121464T1
Authority
CY
Cyprus
Prior art keywords
treatment
habitic
encepalopathy
steroid compound
steroid
Prior art date
Application number
CY20191100299T
Other languages
English (en)
Inventor
Magnus DOVERSKOG
Hanns MÖHLER
Vicente FELIPO
Torbjörn BÄCKSTRÖM
Original Assignee
Umecrine Cognition Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Cognition Ab filed Critical Umecrine Cognition Ab
Publication of CY1121464T1 publication Critical patent/CY1121464T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει τη στεροειδή ένωση οξίμη της 3α-αιθυνυλ-3β-υδροξυανδροσταν-17-όνης, ή φαρμακευτικώς αποδεκτό άλας αυτής, για χρήση στην αντιμετώπιση της ηπατικής εγκεφαλοπάθειας.
CY20191100299T 2014-01-29 2019-03-12 Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας CY1121464T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1450089 2014-01-29
PCT/GB2015/050060 WO2015114308A1 (en) 2014-01-29 2015-01-14 Steroid compound for use in the treatment of hepatic encephalopathy

Publications (1)

Publication Number Publication Date
CY1121464T1 true CY1121464T1 (el) 2020-05-29

Family

ID=52544513

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100299T CY1121464T1 (el) 2014-01-29 2019-03-12 Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας

Country Status (24)

Country Link
US (3) US20160339040A1 (el)
EP (1) EP3099306B1 (el)
JP (1) JP6543633B2 (el)
KR (1) KR102324667B1 (el)
CN (2) CN113185566A (el)
AU (1) AU2015212606B2 (el)
BR (1) BR112016017620A2 (el)
CA (1) CA2935015C (el)
CY (1) CY1121464T1 (el)
DK (1) DK3099306T3 (el)
ES (1) ES2714563T3 (el)
HR (1) HRP20190251T1 (el)
HU (1) HUE042242T2 (el)
IL (1) IL246496B (el)
LT (1) LT3099306T (el)
ME (1) ME03351B (el)
MX (1) MX2016008851A (el)
PL (1) PL3099306T3 (el)
PT (1) PT3099306T (el)
RS (1) RS58375B1 (el)
RU (1) RU2684616C2 (el)
SI (1) SI3099306T1 (el)
TR (1) TR201901687T4 (el)
WO (1) WO2015114308A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160339040A1 (en) 2014-01-29 2016-11-24 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
AU2018333099B2 (en) * 2017-09-12 2023-11-23 Eth Zurich Transmembrane pH-gradient polymersomes for the quantification of ammonia in body fluids
IL274893B1 (en) * 2017-11-27 2024-04-01 Umecrine Cognition Ab Pharmaceutical formulation of 3 alpha-ethynyl-3 beta-hydroxyandrostan-17-one oxime
EP4079307A1 (en) 2021-04-20 2022-10-26 Umecrine Cognition AB New medical use
US20230134958A1 (en) * 2021-10-29 2023-05-04 Umecrine Cognition Ab New medical treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2713061A (en) 1951-04-06 1955-07-12 Schering Ag 3-methyl androstanes
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3173932A (en) 1962-11-02 1965-03-16 American Cyanamid Co 15-substituted estra-1, 3, 5(10)-trienes
FR2685332A1 (fr) 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
AU698834B2 (en) 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
WO1999045931A1 (en) 1998-03-11 1999-09-16 Baeckstroem Torbjoern Epiallopregnanolone in the treatment of cns disorders
US6593321B2 (en) 2001-06-11 2003-07-15 Southwest Foundation For Biomedical Research 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CN102512408B (zh) 2004-11-26 2015-11-25 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物
WO2007103162A2 (en) * 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
CA2833976C (en) * 2006-11-21 2016-03-15 Umecrine Ab The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
BRPI0920465A2 (pt) * 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
CN102625699B (zh) 2009-06-08 2014-08-20 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
WO2015048818A1 (en) 2013-09-30 2015-04-02 Hyperion Therapeutics, Inc. Diagnosing, grading, monitoring, and treating hepatic encephalopathy
US20160339040A1 (en) 2014-01-29 2016-11-24 Umecrine Cognition Ab Steroid compound for use in the treatment of hepatic encephalopathy

Also Published As

Publication number Publication date
AU2015212606A1 (en) 2016-07-14
RU2016127558A3 (el) 2018-09-27
DK3099306T3 (en) 2019-03-18
MX2016008851A (es) 2017-03-23
US20180015103A1 (en) 2018-01-18
EP3099306A1 (en) 2016-12-07
RU2684616C2 (ru) 2019-04-10
JP2017507113A (ja) 2017-03-16
LT3099306T (lt) 2019-03-12
US20170056416A1 (en) 2017-03-02
RU2016127558A (ru) 2018-03-05
US20160339040A1 (en) 2016-11-24
PT3099306T (pt) 2019-03-21
JP6543633B2 (ja) 2019-07-10
HUE042242T2 (hu) 2019-06-28
ME03351B (me) 2019-10-20
NZ721622A (en) 2020-11-27
WO2015114308A1 (en) 2015-08-06
KR102324667B1 (ko) 2021-11-10
CN113185566A (zh) 2021-07-30
AU2015212606B2 (en) 2019-11-21
CN106163528A (zh) 2016-11-23
RS58375B1 (sr) 2019-03-29
BR112016017620A2 (pt) 2017-08-08
WO2015114308A8 (en) 2016-07-21
US9801894B2 (en) 2017-10-31
ES2714563T3 (es) 2019-05-29
PL3099306T3 (pl) 2019-06-28
SI3099306T1 (sl) 2019-03-29
EP3099306B1 (en) 2018-12-12
IL246496B (en) 2019-09-26
US10342804B2 (en) 2019-07-09
KR20160105922A (ko) 2016-09-07
HRP20190251T1 (hr) 2019-04-05
TR201901687T4 (tr) 2019-02-21
IL246496A0 (en) 2016-08-31
CA2935015C (en) 2022-05-31
CA2935015A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
NO2021035I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof
NL301111I2 (nl) Entrectinib of een farmaceutisch aanvaardbaar zout daarvan
CY1121464T1 (el) Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας
HRP20190053T1 (hr) Derivati tetrahidronaftalena koji inhibiraju protein mcl-1
MX2021003311A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
DK3466976T3 (da) Anti-her2-antistof-lægemiddelkonjugat
BR112017007053A2 (pt) compostos neuroativos e métodos de utilização deste composto.
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
DK3474804T4 (da) Medicinsk forbinding
DK3192518T3 (da) Anti-inflammatorisk middel
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2017002702A (es) Sondas para la proyección de imagen de la proteína huntingtina.
MX2017002705A (es) Sondas para la proyección de imagen de la proteína huntingtina.
DK3126486T3 (da) Immunassay, der benytter indfangningskonjugat
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DK3583934T3 (da) Biocidholdigt middel
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
ITUB20153201A1 (it) Kit per la chirurgia episclerale.
FI20145146A (fi) Laitteisto ketjukäyttöön
IL264538B (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide
DK3237015T3 (da) Vandopløselige hydroxybisphosphoniske doxorubicinderivater
DK3903774T3 (da) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
EP3413713C0 (de) Desinfektionsmittel
ES1134230Y (es) Cerradura perfeccionada